期刊
CANCER LETTERS
卷 370, 期 1, 页码 85-90出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2015.10.009
关键词
Tumor microenvironment; Tumor-infiltrating immune cells; Checkpoint blockade; CAR T-cell therapy; Chemokine Cytokine
类别
资金
- U.S. National Institutes of Health through National Cancer Institute [CA141975]
- Chinese Academy of Sciences [XDA09030303]
- Cancer Research Institute
- NATIONAL CANCER INSTITUTE [R01CA134563, R01CA141975] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER
Recent exciting progress in cancer immunotherapy has ushered in a new era of cancer treatment. Immunotherapy can elicit unprecedented durable responses in advanced cancer patients that are much greater than conventional chemotherapy. However, such responses only occur in a relatively small fraction of patients. A positive response to immunotherapy usually relies on dynamic interactions between tumor cells and immunomodulators inside the tumor microenvironment (TME). Depending on the context of these interactions, the TME may play important roles to either dampen or enhance immune responses. Understanding the interactions between immunotherapy and the TME is not only critical to dissect the mechanisms of action but also important to provide new approaches in improving the efficiency of current immunotherapies. In this review, we will highlight recent work on how the TME can influence the efficacy of immunotherapy as well as how manipulating the TME can improve current immunotherapy regimens in some cases. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据